[HTML][HTML] IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …
Metabolomics for investigating physiological and pathophysiological processes
DS Wishart - Physiological reviews, 2019 - journals.physiology.org
Metabolomics uses advanced analytical chemistry techniques to enable the high-throughput
characterization of metabolites from cells, organs, tissues, or biofluids. The rapid growth in …
characterization of metabolites from cells, organs, tissues, or biofluids. The rapid growth in …
Mitochondrial DNA variation and cancer
PK Kopinski, LN Singh, S Zhang, MT Lott… - Nature Reviews …, 2021 - nature.com
Variation in the mitochondrial DNA (mtDNA) sequence is common in certain tumours. Two
classes of cancer mtDNA variants can be identified: de novo mutations that act as 'inducers' …
classes of cancer mtDNA variants can be identified: de novo mutations that act as 'inducers' …
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Z Sondka, S Bamford, CG Cole, SA Ward… - Nature Reviews …, 2018 - nature.com
Abstract The Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census
(CGC) is an expert-curated description of the genes driving human cancer that is used as a …
(CGC) is an expert-curated description of the genes driving human cancer that is used as a …
[HTML][HTML] Mechanisms and implications of metabolic heterogeneity in cancer
J Kim, RJ DeBerardinis - Cell metabolism, 2019 - cell.com
Tumors display reprogrammed metabolic activities that promote cancer progression. We
currently possess a limited understanding of the processes governing tumor metabolism in …
currently possess a limited understanding of the processes governing tumor metabolism in …
[HTML][HTML] R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis
Summary R-2-hydroxyglutarate (R-2HG), a metabolite produced by mutant isocitrate
dehydrogenases (IDHs), was recently reported to exhibit anti-tumor activity. However, its …
dehydrogenases (IDHs), was recently reported to exhibit anti-tumor activity. However, its …
Epigenetic therapies for cancer
SE Bates - New England Journal of Medicine, 2020 - Mass Medical Soc
Epigenetic Therapies for Cancer | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial
IK Mellinghoff, M Penas-Prado, KB Peters… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy
is associated with short-and long-term toxicity. Progression to higher tumor grade is …
is associated with short-and long-term toxicity. Progression to higher tumor grade is …
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
CD DiNardo, EM Stein, S de Botton… - … England Journal of …, 2018 - Mass Medical Soc
Background Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to
10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted …
10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted …
Acute myeloid leukaemia
NJ Short, ME Rytting, JE Cortes - The Lancet, 2018 - thelancet.com
For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …